USANA Health Sciences (NYSE:USNA) Hits New 1-Year Low at $60.96

USANA Health Sciences, Inc. (NYSE:USNA) shares reached a new 52-week low during trading on Tuesday . The company traded as low as $60.96 and last traded at $61.35, with a volume of 4772 shares traded. The stock had previously closed at $62.03.

A number of analysts have commented on USNA shares. ValuEngine raised shares of Westpac Banking from a “sell” rating to a “hold” rating in a report on Wednesday, May 22nd. Sidoti lowered shares of OMNOVA Solutions from a “buy” rating to a “neutral” rating and set a $10.00 target price for the company. in a report on Wednesday, July 3rd. Pivotal Research reissued a “buy” rating and issued a $75.00 price target on shares of USANA Health Sciences in a report on Wednesday, July 3rd. Finally, Tigress Financial assumed coverage on shares of USANA Health Sciences in a report on Tuesday, April 16th. They issued a “buy” rating for the company.

The stock has a market capitalization of $1.44 billion, a P/E ratio of 11.42 and a beta of 0.51. The company’s fifty day simple moving average is $72.03.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, April 30th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.02. USANA Health Sciences had a net margin of 10.38% and a return on equity of 29.51%. The company had revenue of $272.90 million during the quarter, compared to analyst estimates of $272.20 million. During the same quarter in the previous year, the business earned $1.19 EPS. The firm’s revenue was down 6.5% on a year-over-year basis. Equities analysts predict that USANA Health Sciences, Inc. will post 3.9 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in USNA. Norges Bank acquired a new position in shares of USANA Health Sciences in the 4th quarter valued at $35,531,000. MERIAN GLOBAL INVESTORS UK Ltd grew its holdings in shares of USANA Health Sciences by 54.1% in the 1st quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 363,410 shares of the company’s stock valued at $30,479,000 after buying an additional 127,543 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of USANA Health Sciences by 108.1% in the 1st quarter. JPMorgan Chase & Co. now owns 111,904 shares of the company’s stock valued at $9,385,000 after buying an additional 58,121 shares during the period. Marshall Wace LLP bought a new stake in USANA Health Sciences in the 1st quarter valued at $3,525,000. Finally, Nordea Investment Management AB lifted its position in USANA Health Sciences by 124.0% in the 4th quarter. Nordea Investment Management AB now owns 62,315 shares of the company’s stock valued at $7,337,000 after acquiring an additional 34,500 shares in the last quarter. 59.70% of the stock is owned by institutional investors.

USANA Health Sciences Company Profile (NYSE:USNA)

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

See Also: Stop Order

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.